又一笔10亿美元级别的ADC(抗体偶联药物)授权交易出现了。 2月19日,医药龙头石药集团(01093.HK,股价4.88港元,市值563亿港元)发布公告,称附属公司石药巨石自主研发的靶向ROR1的ADC药物SYS6005已与美国生物技术公司Radiance Biopharma达成独家授权协议,将获得1500万美元首付款,并有资格获得最高1.5亿美元的开发和监管里程碑付款、最高10.75亿美元的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.